Delivery Order SPE2DB24D2205-SPE2DB25FEGZS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, valued at $1,041.42. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,889.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor and represents a continuation of the company's ongoing supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,232.28 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 13, 2025. This competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The award carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,393.01 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 MG/ML SureClick auto-injectors. The contract, awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a firm fixed price delivery order with no set-aside designation. This award was made under a competitive procurement process, reflecting AmerisourceBergen's capability to meet federal pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a delivery order valued at $2,254.40 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/ml SureClick auto-injectors. The contract, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as a...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $42,932.71 by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 20, 2025, and will be fulfilled at the company's Conshohocken facility. The award represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $55,027.37 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This firm fixed-price contract, awarded on August 20, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $1,201.32 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pharmaceutical product, with an ultimate completion date of August 28, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,727.74 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, designated as a firm fixed-price delivery order with no set-aside designation, was competitively awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order...
- The Defense Logistics Agency awarded a $16,007.47 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under AmerisourceBergen's existing...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGZSDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $53,634.27 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed-price, competitively awarded delivery order was issued on September 2, 2025, with an ultimate completion date of September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The order will be fulfilled from the company's Conshohocken facility. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive global pharmaceutical support vehicle enables the contractor to supply a broad range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. REPATHA (evolocumab) is a PCSK9 inhibitor used for managing high cholesterol and cardiovascular disease prevention in eligible military beneficiaries. The non-set-aside award demonstrates AmerisourceBergen's capability to fulfill federal medical supply requirements through open competition and reflects the DLA's ongoing pharmaceutical procurement strategy through its established prime vendor agreements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $53.6k | 9/2/25 |